Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2024 08:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

NOVATO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for Health and Care Excellence (NICE) has issued a final...
January 03, 2024 08:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome

NOVATO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
January 02, 2024 16:05 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NOVATO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
December 21, 2023 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
December 18, 2023 08:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

NOVATO, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Commission (EC) has extended the approval of Evkeeza® (evinacumab) as...
December 11, 2023 08:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx anuncia la aprobación de Crysvita® (burosumab) en México para el tratamiento de adultos que viven con hipofosfatemia ligada al cromosoma X (XLH)

CIUDAD DE MÉXICO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una compañía biofarmacéutica especializada en el desarrollo de productos novedosos para...
November 20, 2023 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Participate at Investor Conferences in November

6th Annual Evercore ISI HealthCONx on November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) --...
November 17, 2023 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
November 07, 2023 17:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Participate in the Jefferies London Healthcare Conference

NOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
November 06, 2023 02:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

ROMA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), azienda biofarmaceutica focalizzata sullo sviluppo e la commercializzazione di nuove terapie per malattie...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right